Merck’s keytruda keeps cash flowing as terns buyout, cost cuts fuel stock surge

In a strategic move to diversify and strengthen its late-stage oncology and hematology pipeline ahead of Keytruda's patent expiry, Merck completed the acquisition of Terns Pharmaceuticals, initially valued at $7.7 billion but finalized at $6.7 billion following competitive dynamics and a review of Phase 1 data on TERN-701. This investigational oral CML treatment, which holds FDA Breakthrough Therapy Designation for certain Philadelphia chromosome-positive patients, represents a promising addition to Merck's portfolio, complementing its recent acquisitions of Cidara Therapeutics and Verona Pharma to bolster its oncology pipeline.

While the acquisition of Terns Pharmaceuticals enhances Merck's hematology offerings with TERN-701, it also carries near-term financial implications, including a $2.35 per share charge and an anticipated reduction in 2026 earnings per share by approximately $0.12 due to development and financing costs. This reflects Merck's willingness to absorb short-term financial impacts to secure long-term growth and leadership in oncology.

Keytruda has firmly established itself as Merck’s financial cornerstone, consistently driving record-breaking sales that topped $8 billion quarterly by late 2025, reflecting a robust 10-12% year-over-year growth. By early 2026, despite broader company losses and market challenges, Keytruda’s sales surged another 12% to $8 billion, accounting for nearly half of Merck’s total $16.3 billion quarterly revenue and underscoring its critical role as a growth engine.

Amid looming patent expirations, Merck has strategically bolstered investor confidence by coupling Keytruda’s strong sales momentum with a proactive $3 billion cost-cutting initiative aimed at 2027 and a sharpened focus on product innovation. This approach has helped the company not only to narrow and raise its 2026 profit forecast midpoint to $5.04–$5.16 per share but also to weather acquisition-related charges, demonstrating Keytruda’s pivotal role in sustaining Merck’s financial resilience.

Keytruda’s sustained sales strength has been instrumental in Merck consistently exceeding quarterly sales forecasts and driving a remarkable 20% surge in its stock price over six months, outperforming the S&P 500 by 6.8%. This blockbuster cancer drug remains the primary catalyst behind Merck’s recent growth trajectory, reinforcing its status as an indispensable revenue engine amid ongoing market pressures.

By early 2026, Merck reported a first-quarter loss primarily driven by a $3.62 per share acquisition-related charge from its purchase of Cidara Therapeutics, which overshadowed strong core business performance including a 12% jump in Keytruda sales. Despite this, the adjusted loss of $1.28 per share exceeded analyst expectations, underscoring that the setback was due to one-time acquisition costs rather than operational weaknesses. Concurrently, Merck raised and narrowed its 2026 profit forecast midpoint to $5.04–$5.16 per share on projected sales of $65.8–$67 billion, excluding the planned Terns Pharmaceuticals acquisition, signaling robust confidence in its underlying business strength.

Following Merck’s $5.8 billion acquisition of Terns Pharmaceuticals in early May 2026, the company recorded a significant $2.35 per share charge and anticipated a modest $0.12 per share reduction in 2026 EPS due to development and financing costs. This acquisition-related financial impact, while notable, did not deter investor enthusiasm; an analyst promptly raised Merck’s price target by $1 after the company beat Q1 earnings estimates, reflecting growing market confidence in Merck’s strategic growth trajectory.

Over the subsequent six months, Merck’s stock surged 20%, outperforming the S&P 500 by 6.8%, a rally fueled by strong quarterly results and the blockbuster success of Keytruda. This market outperformance coincided with a substantial improvement in Merck’s adjusted operating margin, which climbed to 27.8% over the trailing 12 months, driven by sales growth and operating leverage. However, despite these gains, Merck’s constant currency revenue growth averaged a modest 4.6% year-on-year over the past two years, slightly lagging the sector and hinting at potential challenges in sustaining demand without further price adjustments or product innovation.

Facing the looming patent expiration of its blockbuster drug Keytruda, Merck has embarked on an ambitious $3 billion cost-cutting initiative through 2027 to safeguard profitability. This strategic move is complemented by leveraging its massive scale—boasting $65.77 billion in revenue over the past year—to negotiate better terms with suppliers, effectively reducing costs in a low-margin, volume-driven pharmaceutical landscape. By early 2026, these efforts contributed to a remarkable 14.5 percentage point increase in Merck’s adjusted operating margin over two years, reaching 27.8%, underscoring the company’s success in translating scale and cost discipline into improved financial performance.

Merck’s operational efficiency narrative is further complicated by external pricing pressures, as CEO Robert Davis publicly acknowledged ongoing negotiations with the White House on drug pricing. This engagement highlights Merck’s proactive approach to navigating the challenging political and market environment, balancing the need for profitability with the realities of heightened scrutiny on pharmaceutical pricing. Such dialogues are critical as Merck seeks to maintain its competitive edge and manage revenue risks amid evolving healthcare policies.

By early 2026, Merck’s pipeline development is anchored by significant late-stage clinical progress and critical regulatory reviews, particularly surrounding assets like WELIREG, enlicitide, and MK-3000. Analyst focus on dosing strategies, trial risks, and FDA review details underscores the high stakes of these milestones, which are poised to drive the company’s future growth trajectory and sustain its competitive edge in oncology and beyond.

Merck’s strategic growth is further propelled by the successful launch and increasing uptake of new products such as IDVYNSO and NUMELVI, which, alongside the integration of recent acquisitions, are expected to significantly bolster revenue streams. This dual approach of expanding the commercial portfolio while assimilating acquired assets highlights Merck’s commitment to reinforcing its market position amid evolving industry dynamics.

Looking ahead, sustaining Merck’s market momentum will depend not only on regulatory approvals and late-stage pipeline advancements but also on effective commercial execution and innovative strategic partnerships, including those leveraging AI technologies. These factors remain under close scrutiny by analysts, as their successful navigation could amplify Merck’s growth potential and solidify its leadership in a competitive pharmaceutical landscape.